adverse event

You have access
Real-world Analysis of Urinary Protein-to-Creatinine Ratio and Blood Pressure in Lenvatinib Therapy
MASANARI TSUJI, KAZUO KOBAYASHI, KAZUYOSHI KAWAKAMI, NAOKI FUKUDA, TAKASHI YOKOKAWA, YUTARO MAE, KOKI HASHIMOTO, AZUSA SOEJIMA, SHUNGO IMAI, NAOKO YOSHIDA, SATOKO HORI, NAOKI SASAHIRA, MAYU YUNOKAWA and MASAKAZU YAMAGUCHI

Anticancer Research March 2026, 46 (3) 1651-1659; DOI: https://doi.org/10.21873/anticanres.18060
You have access
Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma
RYO SATO, YUTO MATSUSHITA, AYANA TAKEMURA, MOMOKO SUGIYAMA, KYOHEI WATANABE, HIROMITSU WATANABE, KEITA TAMURA, DAISUKE MOTOYAMA, MASAO NAGATA, ATSUSHI OTSUKA, HIROSHI FURUSE and HIDEAKI MIYAKE

Anticancer Research February 2024, 44 (2) 781-786; DOI: https://doi.org/10.21873/anticanres.16869
Open Access
Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma
HISANORI MUTO, TEIJI KUZUYA, NAOTO KAWABE, EIZABURO OHNO, KOHEI FUNASAKA, MITSUO NAGASAKA, YOSHIHITO NAKAGAWA, RYOJI MIYAHARA, TOMOYUKI SHIBATA, SENJU HASHIMOTO, YOSHIAKI KATANO and YOSHIKI HIROOKA

Anticancer Research October 2023, 43 (10) 4673-4682; DOI: https://doi.org/10.21873/anticanres.16663
You have access
Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors
MINEHIKO INOMATA, MASAHIRO MATSUMOTO, KANA HAYASHI, ZENTA SETO, TAKAHIRO HIRAI, KOTARO TOKUI, CHIHIRO TAKA, SEISUKE OKAZAWA, KENTA KAMBARA, SHINGO IMANISHI, TOSHIRO MIWA, RYUJI HAYASHI, SHOKO MATSUI and KAZUYUKI TOBE

Anticancer Research July 2023, 43 (7) 3241-3246; DOI: https://doi.org/10.21873/anticanres.16498
You have access
Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy
MARIKO KAMIYA, SHINNOSUKE KAWAHARA, YUTO KAMIOKA, MASAAKI MURAKAWA, TORU AOYAMA, SATOSHI KOBAYASHI, MAKOTO UENO, NAOTO YAMAMOTO, TAKASHI OSHIMA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA and SOICHIRO MORINAGA

Anticancer Research April 2023, 43 (4) 1741-1747; DOI: https://doi.org/10.21873/anticanres.16327
You have access
Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients
MASAAKI TANDA, KAZUHIRO YAMAMOTO, TOMOKI HORI, HIROKI NISHIGUCHI, MIKI YAGI, MICHIKO SHIMIZU, TORU KONISHI, TOMONORI OZAKI, NATSUE YOSHIOKA, MOTOKO TACHIHARA, TAKEFUMI ITO, SHIGEKI IKUSHIMA, TOMOHIRO OMURA and IKUKO YANO

Anticancer Research April 2023, 43 (4) 1775-1783; DOI: https://doi.org/10.21873/anticanres.16331
You have access
Preoperative S-1 Therapy for Head and Neck Carcinoma During the Waiting Period Before Surgery
TAKASHI MATSUKI, CHIHIRO FUSHIMI, SHUNSUKE MIYAMOTO, HIDEAKI TAKAHASHI, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, SHIN-ETSU KAMATA, KOICHI KANO, SHOHEI TSUTSUMI, KAHO MOMIYAMA and TAKU YAMASHITA

Anticancer Research June 2022, 42 (6) 3177-3183; DOI: https://doi.org/10.21873/anticanres.15807
You have access
Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
KOICHI OKAMOTO, ITASU NINOMIYA, HIROTO SAITO, MARI SHIMADA, TAKAHISA YAMAGUCHI, SHIRO TERAI, HIDEKI MORIYAMA, JUN KINOSHITA, KEISHI NAKAMURA and NORIYUKI INAKI

Anticancer Research May 2022, 42 (5) 2783-2790; DOI: https://doi.org/10.21873/anticanres.15758
You have access
Risk–benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer
MICHIO KIMURA, EISEKI USAMI, HITOMI TERAMACHI and TOMOAKI YOSHIMURA

Anticancer Research June 2021, 41 (6) 3091-3097; DOI: https://doi.org/10.21873/anticanres.15093
You have access
Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer
TAITO NAKANO, YOSHIFUMI KADONO, HIROAKI IWAMOTO, HIROSHI YAEGASHI, MASASHI IIJIMA, SHOHEI KAWAGUCHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, KOUJI IZUMI and ATSUSHI MIZOKAMI

Anticancer Research April 2020, 40 (4) 2291-2296; DOI: https://doi.org/10.21873/anticanres.14194

Main menu

User menu

Search

adverse event

Pages